Survival of patients with non-viral hepatocellular carcinoma treated with trans-arterial chemoembolization: A multicenter cohort study

IF 1.1 4区医学 Q4 GASTROENTEROLOGY & HEPATOLOGY

Arab Journal of Gastroenterology Pub Date : 2025-02-01 DOI:10.1016/j.ajg.2024.12.003

Hend Ibrahim Shousha , Eman M.F. Barakat , Eman Rewisha , Mohamed El-Kassas , Ehab Fawzy Moustafa , Mohamed Said , Ashraf Omar Abdelaziz , Safaa Ragab Askar , Eman Elkhateeb , Ahmed Tawheed , Mohamed Omar Abdelmalek , Ahmed Ramadan , Ahmed Hosni Abdelmaksoud , Mostafa Abd Alfattah Shamkh , Hamdy Sayed , Ahmed Radwan Riad , Anwar nassief , Mohamed Mahmoud Nabeel , Yasser Arafat Abdelrazek , Nermeen Abdeen , Mohamed Kohla

{"title":"Survival of patients with non-viral hepatocellular carcinoma treated with trans-arterial chemoembolization: A multicenter cohort study","authors":"Hend Ibrahim Shousha , Eman M.F. Barakat , Eman Rewisha , Mohamed El-Kassas , Ehab Fawzy Moustafa , Mohamed Said , Ashraf Omar Abdelaziz , Safaa Ragab Askar , Eman Elkhateeb , Ahmed Tawheed , Mohamed Omar Abdelmalek , Ahmed Ramadan , Ahmed Hosni Abdelmaksoud , Mostafa Abd Alfattah Shamkh , Hamdy Sayed , Ahmed Radwan Riad , Anwar nassief , Mohamed Mahmoud Nabeel , Yasser Arafat Abdelrazek , Nermeen Abdeen , Mohamed Kohla","doi":"10.1016/j.ajg.2024.12.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and study aims</h3><div>Few studies have considered patients treated with <em>trans</em>-arterial chemoembolization (TACE) for non-viral-induced hepatocellular carcinoma (HCC), with some reporting that those patients may have larger tumors, emphasizing the need for determination of the factors affecting survival in such patients. This work aims to study the characteristics and survival of patients with non-viral related HCC treated with TACE.</div></div><div><h3>Patients and methods</h3><div>This is a multicenter observational study. Patients (166) with non-viral related HCC treated with TACE were recruited from six tertiary care centers (January 2008- June 2022). Follow-up continued until death or the end of the study (August 2023).</div></div><div><h3>Results</h3><div>The patients had a mean age of 60.2 ± 9.5 years, a male predominance of 79.5 %. The mean size of the lesions was 5.71 ± 3.02 cm, and 42.8 % of the patients had a single lesion. After a median follow-up period of 27.02 months (IQR 14.99–39.37), the median overall survival (OS) was 42.14 months. The Cox regression hazard model revealed that the independent factors affecting survival were: multiple focal lesions, exceeding five in number, have a substantially higher hazard of death (HR = 8.5, p-value = 0.001) compared to those with a single focal lesion. HAP score grade D exhibited a threefold increase in the hazard of death (HR = 3.8, p-value 0.007). Individuals who did not respond positively to treatment faced a significantly higher risk of death (HR = 10.76, p-value 0.001). Albumin-bilirubin score (ALBI), Easy ALBI, platelet albumin (PAL), platelet albumin bilirubin score (PALBI), The hepatoma arterial-embolisation (HAP) and Tumor burden score were found not to impact the survival of our patients.</div></div><div><h3>Conclusion</h3><div>Tumor burden is an important determinant of survival after TACE in patients with non-viral HCC. HAP score can be implemented in selecting patients who would benefit from TACE.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"26 1","pages":"Pages 94-103"},"PeriodicalIF":1.1000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arab Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S168719792400131X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and study aims

Few studies have considered patients treated with trans-arterial chemoembolization (TACE) for non-viral-induced hepatocellular carcinoma (HCC), with some reporting that those patients may have larger tumors, emphasizing the need for determination of the factors affecting survival in such patients. This work aims to study the characteristics and survival of patients with non-viral related HCC treated with TACE.

Patients and methods

This is a multicenter observational study. Patients (166) with non-viral related HCC treated with TACE were recruited from six tertiary care centers (January 2008- June 2022). Follow-up continued until death or the end of the study (August 2023).

Results

The patients had a mean age of 60.2 ± 9.5 years, a male predominance of 79.5 %. The mean size of the lesions was 5.71 ± 3.02 cm, and 42.8 % of the patients had a single lesion. After a median follow-up period of 27.02 months (IQR 14.99–39.37), the median overall survival (OS) was 42.14 months. The Cox regression hazard model revealed that the independent factors affecting survival were: multiple focal lesions, exceeding five in number, have a substantially higher hazard of death (HR = 8.5, p-value = 0.001) compared to those with a single focal lesion. HAP score grade D exhibited a threefold increase in the hazard of death (HR = 3.8, p-value 0.007). Individuals who did not respond positively to treatment faced a significantly higher risk of death (HR = 10.76, p-value 0.001). Albumin-bilirubin score (ALBI), Easy ALBI, platelet albumin (PAL), platelet albumin bilirubin score (PALBI), The hepatoma arterial-embolisation (HAP) and Tumor burden score were found not to impact the survival of our patients.

Conclusion

Tumor burden is an important determinant of survival after TACE in patients with non-viral HCC. HAP score can be implemented in selecting patients who would benefit from TACE.

查看原文本刊更多论文

经动脉化疗栓塞治疗的非病毒性肝细胞癌患者的生存率：一项多中心队列研究

背景和研究目的：很少有研究考虑经动脉化疗栓塞（TACE）治疗非病毒诱导的肝细胞癌（HCC）的患者，一些研究报道这些患者可能有较大的肿瘤，强调需要确定影响此类患者生存的因素。本研究旨在研究TACE治疗非病毒相关性HCC患者的特点和生存率。患者和方法：这是一项多中心观察性研究。从六个三级医疗中心（2008年1月至2022年6月）招募了接受TACE治疗的非病毒性相关性HCC患者（166例）。随访一直持续到死亡或研究结束（2023年8月）。结果：患者平均年龄60.2±9.5岁，男性占79.5%。病灶的平均大小为5.71±3.02 cm， 42.8%的患者为单发病灶。中位随访期为27.02个月（IQR 14.99 ~ 39.37），中位总生存期（OS）为42.14个月。Cox回归风险模型显示，影响生存的独立因素为：多灶性病变数量超过5个，死亡风险显著高于单灶性病变（HR = 8.5， p值= 0.001）。HAP评分D级患者死亡风险增加3倍（HR = 3.8， p值0.007）。对治疗无积极反应的个体面临着显著更高的死亡风险（HR = 10.76， p值0.001）。白蛋白-胆红素评分（ALBI）、Easy ALBI、血小板白蛋白（PAL）、血小板白蛋白-胆红素评分（PALBI）、肝癌动脉栓塞（HAP）和肿瘤负荷评分均不影响患者的生存。结论：肿瘤负荷是非病毒性HCC患者TACE术后生存的重要决定因素。HAP评分可用于选择从TACE获益的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arab Journal of Gastroenterology Medicine-Gastroenterology

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： Arab Journal of Gastroenterology (AJG) publishes different studies related to the digestive system. It aims to be the foremost scientific peer reviewed journal encompassing diverse studies related to the digestive system and its disorders, and serving the Pan-Arab and wider community working on gastrointestinal disorders.